Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-3: mevrometostat plus enzalutamide versus placebo plus enzalutamide in metastatic castration-sensitive prostate cancer
NL-OMON60361Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Mevrometostat + enzalutamide with Placebo + enzalutamide (2 arms). Primary endpoint: Radiographic progression-free survival. Started Feb 2026; status: active, not recruiting.
02
Drugs
mevrometostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON60361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60361.